Browsing Tag
Firmonertinib
1 post
ArriVent shares plunge as FURVENT miss shifts attention to PACC lung cancer and ADC pipeline
ArriVent shares plunge after firmonertinib misses the FURVENT Phase 3 endpoint, putting its first-line exon 20 lung cancer strategy at risk.